Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:6892's Gross Margin % is ranked worse than 54.23% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:6892: 56.94
Taiwan Bio Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Taiwan Bio Therapeutics was 0.00% per year.
Taiwan Bio Therapeutics (ROCO:6892) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Taiwan Bio Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Taiwan Bio Therapeutics Gross Margin % Related Terms
Taiwan Bio Therapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Taiwan Bio Therapeutics (ROCO:6892) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Taiwan Bio Therapeutics and its competitors. Over the past decade, Taiwan Bio Therapeutics' Gross Margin % has ranged from 53.35 to 89.34. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #397 out of 732 companies in the Biotechnology industry, placing it in the top 54.2%.
Is Taiwan Bio Therapeutics' Gross Margin % too high?
Taiwan Bio Therapeutics' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 53.35 to a high of 89.34. Based on the distribution chart, Taiwan Bio Therapeutics ranks #397 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #397 out of 732 companies for Gross Margin %. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Taiwan Bio Therapeutics' own Gross Margin % has ranged from 53.35 to 89.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.66, compared to a current price of NT$26.90 — trading 83.5% above its estimated fair value. The current Gross Margin % is 0.00%. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$26.90 is trading 83.5% above its estimated GF Value™ of NT$14.66.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
Gross Margin %: 0.00%
GF Value™: NT$14.66 vs. price of NT$26.90 (83.5% above fair value)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score
Get the complete analysis for ROCO:6892
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
